Medicine and Dentistry
Chronic Myelogenous Leukemia
100%
Imatinib
100%
Leukemia Cell
100%
Activin A
100%
Programmed Cell Death
28%
p38 Mitogen-Activated Protein Kinase
28%
Growth Inhibition
28%
Multidrug Resistance
14%
Glycophorin A
14%
Procaspase 3
14%
Disease
7%
Cell Differentiation
7%
Short Hairpin RNA
7%
SB 203580
7%
Group Therapy
7%
Bcl-xL
7%
Poly ADP Ribose Polymerase
7%
BCR ABL Protein
7%
Progenitor Cell Line
7%
RNA Knockdown
7%
Cytotoxicity
7%
Progenitor Cell
7%
Transforming Growth Factor
7%
Biochemistry, Genetics and Molecular Biology
Imatinib
100%
Activin
100%
Myeloid
100%
P38 Mitogen-Activated Protein Kinases
28%
Growth Inhibition
28%
Multidrug Resistance
14%
Glycophorin
14%
Progenitor Cell
14%
Cellular Differentiation
7%
Bcl-xL
7%
RNA Knockdown
7%
SB 203580
7%
Cytotoxicity
7%
Small Hairpin RNA
7%
Transforming Growth Factor
7%
Poly ADP Ribose Polymerase
7%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Myeloid Leukemia
100%
Activin A
100%
Imatinib
100%
Multiple Drug Resistance
14%
Procaspase 3
14%
Glycophorin A
14%
Cytotoxicity
7%
Short Hairpin RNA
7%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
7%
SB 203580
7%
BCR ABL Protein
7%
Disease
7%
Transforming Growth Factor
7%